ASH 2019 Archives - Medical Conferences

Home > Haematology > ASH 2019

American Society of Hematology

7–10 December 2019 Orlando, Florida, USA

Letter from the Editor

Editor

Prof. Gert Ossenkoppele, VU University Medical Center, the Netherlands

Late-Breaking Abstracts

Likely new standard of care: Blinatumomab for children with relapsed B-ALL

Presented By

Prof. Patrick A. Brown, Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Pivotal phase 3 trial in cold agglutinin disease: sutimlimab can stop haemolysis

Presented By

Dr Alexander Röth, University of Duisburg-Essen, Germany

Oral azacitidine improves overall survival in patients with AML in remission

Presented By

Dr Andrew Wei, Alfred Hospital, Australia

BCL11A as a novel target in gene therapy for sickle cell disease

Presented By

Dr David Williams, Boston Children’s Hospital, USA

Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

Presented By

Prof. Saad Usmani, UNC-Chapel Hill School of Medicine, USA

Long-term data of ropeginterferon alpha-2b in polycythaemia vera

Presented By

Prof. Jean-Jacques Kiladjian, Saint Louis Hospital, France

Anti-CD70 is safe with hypomethylating agents in AML

Presented By

Prof. Adrian Ochsenbein, Bern University Hospital, Switzerland

MRD assessment to guide pre-emptive treatment decisions

Presented By

Prof. Uwe Platzbecker, University Hospital Carl Gustav Carus, Germany

Luspatercept effective for myelofibrosis-associated anaemia

Presented By

Prof. Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, USA

Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance

Presented By

Prof. Gill Singh, University of Hong Kong, China

Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT

Presented By

Dr Xiaowen Tang; Dr James Foran

Sickle Cell Disease

Arginine supplements help against sickle cell disease pain

Presented By

Prof. Richard Onalo, University of Abuja, Nigeria

Abatacept prevents graft-versus-host disease in sickle cell patients after alloSCT

Presented By

Dr Niketa Shah, Yale University, USA

Plenary Scientific Session

HOVON-96: Better outcomes with cyclophosphamide after transplantation

Presented By

Dr Annoek Broers, Erasmus MC Cancer Institute, the Netherlands

Erythroferrone and skeletal changes associated with thalassaemia

Presented By

Dr Melanie Castro-Mollo, Icahn School of Medicine at Mount Sinai, USA

Gene editing in congenital neutropenia

Presented By

Dr Shuquan Rao, Harvard Medical School, USA

Experimental model for limitations of haematopoietic stem cells propagation

Presented By

Dr Jennifer Myers SanMiguel, The Jackson Laboratory, USA

Mosunetuzumab: complete remissions in non-Hodgkin lymphoma

Presented By

Prof. Stephen Schuster, University of Pennsylvania, USA

Inclusive Medicine

Socioeconomic disparities and survival in paediatric AML

Presented By

Dr Lena Winestone, UCSF Benioff Children’s Hospital, USA

Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma

Presented By

Dr Christine Chen, Princess Margaret Cancer Centre, University of Toronto, Canada

CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients

Presented By

Dr Karl Kilgore, Avalere, USA

Mild renal impairment in African Americans does not affect OS in AML

Presented By

Dr Abby Statler, Cleveland Clinic, USA

ALCYONE: New overall survival results for myeloma

Presented By

Dr Maria Victoria Mateos, University Hospital of Salamanca, Spain

Venous Thromboembolism

Rivaroxaban is safe and effective for paediatric venous thromboembolism

Presented By

Prof. Guy Young, Children's Hospital Los Angeles, USA

Aspirin plus DOAC is not better than a DOAC alone

Presented By

Prof. Jordan Schaefer, University of Michigan, USA

20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon

Presented By

Dr Maria Vazquez, MD Anderson Cancer Center, Houston, USA

CAR T and Beyond

BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM

Presented By

Dr Deepu Madduri, Mount Sinai Medical Center, USA

Anti-BCMA/anti-CD38 in refractory multiple myeloma

Presented By

Prof. Yu Hu, Huazhong University of Science and Technology, China

Off-the-shelf natural killer cells

Presented By

Dr Jode Goodridge, Fate Therapeutics, USA

Medical Conferences

ASH 2019

Table of Contents

Featured articles

Letter from the Editor

Late-Breaking Abstracts

Likely new standard of care: Blinatumomab for children with relapsed B-ALL

Pivotal phase 3 trial in cold agglutinin disease: sutimlimab can stop haemolysis

Oral azacitidine improves overall survival in patients with AML in remission

BCL11A as a novel target in gene therapy for sickle cell disease

Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM

Long-term data of ropeginterferon alpha-2b in polycythaemia vera

Anti-CD70 is safe with hypomethylating agents in AML

MRD assessment to guide pre-emptive treatment decisions

Luspatercept effective for myelofibrosis-associated anaemia

Arsenic, ATRA, and ascorbic acid in acute promyelocytic leukaemia maintenance

Updated results ECOG-ACRIN E2906: decitabine maintenance after alloSCT

Sickle Cell Disease

Arginine supplements help against sickle cell disease pain

Abatacept prevents graft-versus-host disease in sickle cell patients after alloSCT

Plenary Scientific Session

HOVON-96: Better outcomes with cyclophosphamide after transplantation

Erythroferrone and skeletal changes associated with thalassaemia

Gene editing in congenital neutropenia

Experimental model for limitations of haematopoietic stem cells propagation

Mosunetuzumab: complete remissions in non-Hodgkin lymphoma

Inclusive Medicine

Socioeconomic disparities and survival in paediatric AML

Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma

CAR T-cell therapy successful in older non-Hodgkin’s lymphoma patients

Mild renal impairment in African Americans does not affect OS in AML

ALCYONE: New overall survival results for myeloma

Venous Thromboembolism

Rivaroxaban is safe and effective for paediatric venous thromboembolism

Aspirin plus DOAC is not better than a DOAC alone

20-Year follow-up of imatinib in chronic myeloid leukaemia after failure with interferon

CAR T and Beyond

BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM

Anti-BCMA/anti-CD38 in refractory multiple myeloma

Off-the-shelf natural killer cells